Fibroblast growth factor receptors: Multifactorialcontributors to tumor initiation and progression

Histology and Histopathology

Volumn 30, Issue 1, 2015, Pages 13-31

  Feng, Shachuan ^a,b   Zhou, Li ^a,b   Nice, Edouard Collins ^c   Huang, Canhua ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Fibroblast growth factor receptor; Genetic and epigenetic alterations; Signaling; Tumorigenesis

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR;

CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE COURSE; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84916613814     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (199)

1. Acevedo V.D., Gangula R.D., Freeman K.W., Li R., Zhang Y., Wang F., Ayala G.E., Peterson L.E., Ittmann M. and Spencer D.M. (2007). Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12, 559-571.
2. Ahmad I., Iwata T. and Leung H.Y. (2012). Mechanisms of FGFRmediated carcinogenesis. Biochim. Biophys. Acta 1823, 850-860.
3. Al-Otaiby M., Tassi E., Schmidt M.O., Chien C.D., Baker T., Salas A.G., Xu J., Furlong M., Schlegel R., Riegel A.T. and Wellstein A. (2012). Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing. Am. J. Pathol. 180, 1474-1484.
4. Amann R. and Trueb B. (2013). Evidence that the novel receptor FGFRL1 signals indirectly via FGFR1. Int. J. Mol. Med. 32, 983-988.
5. Amann T., Bataille F., Spruss T., Dettmer K., Wild P., Liedtke C., Muhlbauer M., Kiefer P., Oefner P.J., Trautwein C., Bosserhoff A.K. and Hellerbrand C. (2010). Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am. J. Pathol. 176, 1433-1442.
6. Arai Y., Totoki Y., Hosoda F., Shirota T., Hama N., Nakamura H., Ojima H., Furuta K., Shimada K., Okusaka T., Kosuge T. and Shibata T. (2014). Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427-1434.
7. Ardi V.C., Van den Steen P.E., Opdenakker G., Schweighofer B., Deryugina E.I. and Quigley J.P. (2009). Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J. Biol. Chem. 284, 25854-25866.
8. Auguste P., Gursel D.B., Lemiere S., Reimers D., Cuevas P., Carceller F., Di Santo J.P. and Bikfalvi A. (2001). Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and-independent mechanisms. Cancer Res. 61, 1717-1726.
9. Balkwill F., Charles K.A. and Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217.
10. Becker D., Lee P.L., Rodeck U. and Herlyn M. (1992). Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 7, 2303-2313.
11. Belov A.A. and Mohammadi M. (2013). Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold. Spring. Harb. Perspect. Biol. 5.
12. Bernard-Pierrot I., Ricol D., Cassidy A., Graham A., Elvin P., Caillault A., Lair S., Broet P., Thiery J.P. and Radvanyi F. (2004). Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene 23, 9201-9211.
13. Betts G., Valentine H., Pritchard S., Swindell R., Williams V., Morgan S., Griffiths E.A., Welch I., West C. and Womack C. (2014). FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch. 464, 145-156.
14. Bian X.W., Du L.L., Shi J.Q., Cheng Y.S. and Liu F.X. (2000). Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Anal. Quant. Cytol. Histol. 22, 267-274.
15. Billottet C., Tuefferd M., Gentien D., Rapinat A., Thiery J.P., Broet P. and Jouanneau J. (2008). Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells. J. Cell. Biochem. 104, 826-839.
16. Blick C., Ramachandran A., Wigfield S., McCormick R., Jubb A., Buffa F.M., Turley H., Knowles M.A., Cranston D., Catto J. and Harris A.L. (2013). Hypoxia regulates FGFR3 expression via HIF-1alpha and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. Br. J. Cancer. 109, 50-59.
17. Bojesen K.B., Clausen O., Rohde K., Christensen C., Zhang L., Li S., Kohler L., Nielbo S., Nielsen J., Gjorlund M.D., Poulsen F.M., Bock E. and Berezin V. (2012). Nectin-1 binds and signals through the fibroblast growth factor receptor. J. Biol. Chem. 287, 37420-37433.
18. Boscher C. and Mege R.M. (2008). Cadherin-11 interacts with the FGF receptor and induces neurite outgrowth through associated downstream signalling. Cell Signal. 20, 1061-1072.
19. Brown K.J., Hendry I.A. and Parish C.R. (1995). Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c 3T3 cells: implications for potentiation of growth factor action by heparin. J. Cell. Biochem. 58, 6-14.
20. Brunello E., Brunelli M., Bogina G., Calio A., Manfrin E., Nottegar A., Vergine M., Molino A., Bria E., Massari F., Tortora G., Cingarlini S., Pedron S., Chilosi M., Zamboni G., Miller K., Martignoni G. and Bonetti F. (2012). FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J. Exp. Clin. Cancer Res. 31, 103.
21. Bryant D.M., Wylie F.G. and Stow J.L. (2005). Regulation of endocytosis, nuclear translocation, and signaling of fibroblast growth factor receptor 1 by E-cadherin. Mol. Biol. Cell 16, 14-23.
22. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P. and Radvanyi F. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20.
23. Catto J.W., Alcaraz A., Bjartell A.S., De Vere White R., Evans C.P., Fussel S., Hamdy F.C., Kallioniemi O., Mengual L., Schlomm T. and Visakorpi T. (2011). MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 59, 671-681.
24. Catto J.W., Miah S., Owen H.C., Bryant H., Myers K., Dudziec E., Larre S., Milo M., Rehman I., Rosario D.J., Di Martino E., Knowles M.A., Meuth M., Harris A.L. and Hamdy F.C. (2009). Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res. 69, 8472-8481.
25. Cavallaro U. and Christofori G. (2004). Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann. NY Acad. Sci. 1014, 58-66.
26. Cavallaro U., Niedermeyer J., Fuxa M. and Christofori G. (2001). NCAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signalling. Nat. Cell Biol. 3, 650-657.
27. Cerliani J.P., Guillardoy T., Giulianelli S., Vaque J.P., Gutkind J.S., Vanzulli S.I., Martins R., Zeitlin E., Lamb C.A. and Lanari C. (2011). Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 71, 3720-3731.
28. Chakrabarti M., Banik N.L. and Ray S.K. (2013). Photofrin based photodynamic therapy and miR-99a transfection inhibited FGFR3 and PI3K/Akt signaling mechanisms to control growth of human glioblastoma In vitro and in vivo. PLoS One 8, e55652.
29. Chamorro-Jorganes A., Araldi E., Penalva L.O., Sandhu D., Fernandez-Hernando C. and Suarez Y. (2011). MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler. Thromb. Vasc. Biol. 31, 2595-2606.
30. Chen W., Wang G.M., Guo J.M., Sun L.A. and Wang H. (2012). NGF/gamma-IFN inhibits androgen-independent prostate cancer and reverses androgen receptor function through downregulation of FGFR2 and decrease in cancer stem cells. Stem Cells Dev. 21, 3372-3380.
31. Chioni A.M. and Grose R. (2012). FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J. Cell Biol. 197, 801-817.
32. Choi K.Y., Rho Y.S., Kwon K.H., Chung E.J., Kim J.H., Park I.S. and Lee D.J. (2012). ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma. Cancer Biomark. 12, 115-124.
33. Clasper S., Vekemans S., Fiore M., Plebanski M., Wordsworth P., David G. and Jackson D.G. (1999). Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J. Biol. Chem. 274, 24113-24123.
34. Coleman S.J., Chioni A.M., Ghallab M., Anderson R.K., Lemoine N.R., Kocher H.M. and Grose R.P. (2014). Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol. Med. 6, 467-481.
35. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotten M. and Christofori G. (2000). Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60, 7163-7169.
36. Cortese R., Hartmann O., Berlin K. and Eckhardt F. (2008). Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int. J. Biochem. Cell. Biol. 40, 1494-1508.
37. Coussens L.M. and Werb Z. (2002). Inflammation and cancer. Nature 420, 860-867.
38. Crose L.E., Etheridge K.T., Chen C., Belyea B., Talbot L.J., Bentley R.C. and Linardic C.M. (2012). FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin. Cancer Res. 18, 3780-3790.
39. D'Amici S., Ceccarelli S., Vescarelli E., Romano F., Frati L., Marchese C. and Angeloni A. (2013). TNFalpha modulates Fibroblast Growth Factor Receptor 2 gene expression through the pRB/E2F1 pathway: identification of a non-canonical E2F binding motif. PLoS One 8, e61491.
40. Deo D.D., Axelrad T.W., Robert E.G., Marcheselli V., Bazan N.G. and Hunt J.D. (2002). Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 277, 21237-21245.
41. Dey J.H., Bianchi F., Voshol J., Bonenfant D., Oakeley E.J. and Hynes N.E. (2010). Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 70, 4151-4162.
42. di Martino E., L'Hote C.G., Kennedy W., Tomlinson D.C. and Knowles M.A. (2009). Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type-and mutation-specific manner. Oncogene 28, 4306-4316.
43. Dieci M.V., Arnedos M., Andre F. and Soria J.C. (2013). Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 3, 264-279.
44. Dienstmann R., Rodon J., Prat A., Perez-Garcia J., Adamo B., Felip E., Cortes J., Iafrate A.J., Nuciforo P. and Tabernero J. (2014). Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 25, 552-563.
45. Doherty P., Smith P. and Walsh F.S. (1996). Shared cell adhesion molecule (CAM) homology domains point to CAMs signalling via FGF receptors. Perspect. Dev. Neurobiol. 4, 157-168.
46. Drafahl K.A., McAndrew C.W., Meyer A.N., Haas M. and Donoghue D.J. (2010). The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling. PLoS One 5, e14412.
47. Du X., Wang Q.R., Chan E., Merchant M., Liu J., French D., Ashkenazi A. and Qing J. (2012). FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res. 72, 5843-5855.
48. Dudka A.A., Sweet S.M. and Heath J.K. (2010). Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. Cancer Res. 70, 3391-3401.
49. Dutra R.L., de Carvalho M.B., Dos Santos M., Mercante A.M., Gazito D., de Cicco R., Group G., Tajara E.H., Louro I.D. and da Silva A.M. (2012). FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One 7, e50747.
50. Eswarakumar V.P., Lax I. and Schlessinger J. (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139-149.
51. Ezzat S., Yu S. and Asa S.L. (2003). Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. Am. J. Pathol. 163, 1177-1184.
52. Fang X., Stachowiak E.K., Dunham-Ems S.M., Klejbor I. and Stachowiak M.K. (2005). Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. J. Biol. Chem. 280, 28451-28462.
53. Fearon A.E., Gould C.R. and Grose R.P. (2013). FGFR signalling in women's cancers. Int. J. Biochem. Cell. Biol. 45, 2832-2842.
54. Feng S., Wang F., Matsubara A., Kan M. and McKeehan W.L. (1997). Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. 57, 5369-5378.
55. Finetti F., Solito R., Morbidelli L., Giachetti A., Ziche M. and Donnini S. (2008). Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J. Biol. Chem. 283, 2139-2146.
56. Folkman J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18.
57. Forootan S.S., Ke Y., Jones A.S. and Helliwell T.R. (2000). Basic fibroblast growth factor and angiogenesis in squamous carcinoma of the tongue. Oral. Oncol. 36, 437-443.
58. Fournier G., Garrido-Urbani S., Reymond N. and Lopez M. (2010). Nectin and nectin-like molecules as markers, actors and targets in cancer. M. S-Medecine. Sciences 26, 273-279.
59. Freeman K.W., Gangula R.D., Welm B.E., Ozen M., Foster B.A., Rosen J.M., Ittmann M., Greenberg N.M. and Spencer D.M. (2003). Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 63, 6237-6243.
60. Friesel R.E. and Maciag T. (1995). Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 9, 919-925.
61. Fukumoto S. (2008). Actions and mode of actions of FGF19 subfamily members. Endocr. J. 55, 23-31.
62. Gadgeel S.M., Chen W., Cote M.L., Bollig-Fischer A., Land S., Schwartz A.G. and Bepler G. (2013). Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR. PLoS One 8, e79820.
63. Gemmill R.M., Roche J., Potiron V.A., Nasarre P., Mitas M., Coldren C.D., Helfrich B.A., Garrett-Mayer E., Bunn P.A. and Drabkin H.A. (2011). ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 300, 66-78.
64. Goke F., Franzen A., Menon R., Goltz D., Kirsten R., Boehm D., Vogel W., Goke A., Scheble V., Ellinger J., Gerigk U., Fend F., Wagner P., Schroeck A. and Perner S. (2012). Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 142, 1020-1026.
65. Goldstein M., Meller I. and Orr-Urtreger A. (2007). FGFR1 overexpression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes Cancer 46, 1028-1038.
66. Gomez-Roman J.J., Saenz P., Molina M., Cuevas Gonzalez J., Escuredo K., Santa Cruz S., Junquera C., Simon L., Martinez A., Gutierrez Banos J.L., Lopez-Brea M., Esparza C. and Val-Bernal J.F. (2005). Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. Cancer Res. 11, 459-465.
67. Gorbenko O., Ovcharenko G., Klymenko T., Zhyvoloup O., Gaman N., Volkova D., Gout I. and Filonenko V. (2009). Generation of monoclonal antibody targeting fibroblast growth factor receptor 3. Hybridoma (Larchmt) 28, 295-300.
68. Guo M., Liu W., Serra S., Asa S.L. and Ezzat S. (2012). FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res. 72, 2017-2027.
69. Hanahan D. and Weinberg R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
70. Hansen S.M., Berezin V. and Bock E. (2008). Signaling mechanisms of neurite outgrowth induced by the cell adhesion molecules NCAM and N-cadherin. Cell. Mol. Life. Sci. 65, 3809-3821.
71. Hart K.C., Robertson S.C. and Donoghue D.J. (2001). Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol. Biol. Cell 12, 931-942.
72. Heinzle C., Gsur A., Hunjadi M., Erdem Z., Gauglhofer C., Stattner S., Karner J., Klimpfinger M., Wrba F., Reti A., Hegedus B., Baierl A., Grasl-Kraupp B., Holzmann K., Grusch M., Berger W. and Marian B. (2012). Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res. 72, 5767-5777.
73. Huang X., Yu C., Jin C., Kobayashi M., Bowles C.A., Wang F. and McKeehan W.L. (2006). Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res. 66, 1481-1490.
74. Huang X.Q., Yang C.F., Jin C.L., Luo Y.D., Wang F. and McKeehan W.L. (2009). Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol. Carcinogenesis 48, 553-562.
75. Huijts P.E., Vreeswijk M.P., Kroeze-Jansema K.H., Jacobi C.E., Seynaeve C., Krol-Warmerdam E.M., Wijers-Koster P.M., Blom J.C., Pooley K.A., Klijn J.G., Tollenaar R.A., Devilee P. and van Asperen C.J. (2007). Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res. 9, R78.
76. Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Wang Z., Welch R., Hutchinson A., Wang J., Yu K., Chatterjee N., Orr N., Willett W.C., Colditz G.A., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Hayes R.B., Tucker M., Gerhard D.S., Fraumeni J.F. Jr, Hoover R.N., Thomas G. and Chanock S.J. (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874.
77. Ishiwata T., Matsuda Y., Yamamoto T., Uchida E., Korc M. and Naito Z. (2012). Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am. J. Pathol. 180, 1928-1941.
78. Issa A., Gill J.W., Heideman M.R., Sahin O., Wiemann S., Dey J.H. and Hynes N.E. (2013). Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res. 15, R8.
79. Jang M., Kim E., Choi Y., Lee H., Kim Y., Kim J., Kang E., Kim S.W., Kim I. and Park S. (2012). FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 14, R115.
80. Jiang H., Qu L., Wang Y., Cong J., Wang W. and Yang X. (2014). miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells. Biomed. Pharmacother. 68, 163-169.
81. Johnston C.L., Cox H.C., Gomm J.J. and Coombes R.C. (1995). Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J. Biol. Chem. 270, 30643-30650.
82. Kalinina J., Dutta K., Ilghari D., Beenken A., Goetz R., Eliseenkova A.V., Cowburn D. and Mohammadi M. (2012). The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 20, 77-88.
83. Kamura S., Matsumoto Y., Fukushi J.I., Fujiwara T., Iida K., Okada Y. and Iwamoto Y. (2010). Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br. J. Cancer 103, 370-381.
84. Karajannis M.A., Vincent L., Direnzo R., Shmelkov S.V., Zhang F., Feldman E.J., Bohlen P., Zhu Z., Sun H., Kussie P. and Rafii S. (2006). Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 20, 979-986.
85. Katoh M. and Nakagama H. (2014). FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 34, 280-300.
86. Kelleher F.C., O'Sullivan H., Smyth E., McDermott R. and Viterbo A. (2013). Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis 34, 2198-2205.
87. Kigel B., Rabinowicz N., Varshavsky A., Kessler O. and Neufeld G. (2011). Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood 118, 4285-4296.
88. Kilkenny D.M. and Hill D.J. (1996). Perinuclear localization of an intracellular binding protein related to the fibroblast growth factor (FGF) receptor 1 is temporally associated with the nuclear trafficking of FGF-2 in proliferating epiphyseal growth plate chondrocytes. Endocrinology 137, 5078-5089.
89. Kokkinakis D.M., Rushing E.J., Shareef M.M., Ahmed M.M., Yang S., Singha U.K. and Luo J. (2004). Physiology and gene expression characteristics of carcinogen-initiated and tumor-transformed glial progenitor cells derived from the CNS of methylnitrosourea (MNU)-treated Sprague-Dawley rats. J. Neuropathol. Exp. Neurol. 63, 1182-1199.
90. Kondo T., Zheng L., Liu W., Kurebayashi J., Asa S.L. and Ezzat S. (2007a). Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 67, 5461-5470.
91. Kondo T., Zhu X.G., Asa S.L. and Ezzat S. (2007b). The cancer/testis antigen melanoma-associated Antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin. Cancer Res. 13, 4713-4720.
92. Kotani N., Ishiura Y., Yamashita R., Ohnishi T. and Honke K. (2012). Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. J. Biol. Chem. 287, 37109-37118.
93. Kulahin N., Li S., Hinsby A., Kiselyov V., Berezin V. and Bock E. (2008). Fibronectin type III (FN3) modules of the neuronal cell adhesion molecule L1 interact directly with the fibroblast growth factor (FGF) receptor. Mol. Cell. Neurosci. 37, 528-536.
94. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., Elbi C. and Lutterbach B. (2008). FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68, 2340-2348.
95. Larrieu-Lahargue F., Welm A.L., Bouchecareilh M., Alitalo K., Li D.Y., Bikfalvi A. and Auguste P. (2012). Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS One 7, e39540.
96. Lee P.S. and Secord A.A. (2014). Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. Cancer. Treat. Rev. 40, 507-512.
97. Lee S.H., Schloss D.J. and Swain J.L. (2000). Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J. Biol. Chem. 275, 33679-33687.
98. Lefevre G., Babchia N., Calipel A., Mouriaux F., Faussat A.M., Mrzyk S. and Mascarelli F. (2009). Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest. Ophth. Vis. Sci. 50, 1047-1057.
99. Lehnen N.C., von Massenhausen A., Kalthoff H., Zhou H., Glowka T., Schutte U., Holler T., Riesner K., Boehm D., Merkelbach-Bruse S., Kirfel J., Perner S. and Gutgemann I. (2013). Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology 63, 157-166.
100. Leite K.R., Morais D.R., Reis S.T., Viana N., Moura C., Florez M.G., Silva I.A., Dip N. and Srougi M. (2013). MicroRNA 100: a context dependent miRNA in prostate cancer. Clinics (Sao Paulo) 68, 797-802.
101. Li M., Seki Y., Freitas P.H., Nagata M., Kojima T., Sultana S., Ubaidus S., Maeda T., Shimomura J., Henderson J.E., Tamura M., Oda K., Liu Z., Guo Y., Suzuki R., Yamamoto T., Takagi R. and Amizuka N. (2010). FGFR3 down-regulates PTH/PTHrP receptor gene expression by mediating JAK/STAT signaling in chondrocytic cell line. J. Elec. Microsc. 59, 227-236.
102. Liu W., Cheng S., Asa S.L. and Ezzat S. (2008). The melanomaassociated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 68, 8104-8112.
103. Liu R., Li J., Xie K., Zhang T., Lei Y., Chen Y., Zhang L., Huang K., Wang K., Wu H., Wu M., Nice E.C., Huang C. and Wei Y. (2013). FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 73, 5926-5935.
104. Magnusson P.U., Dimberg A., Mellberg S., Lukinius A. and Claesson-Welsh L. (2007). FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin. Blood 110, 4214-4222.
105. Maher P.A. (1996). Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J. Cell Biol. 134, 529-536.
106. Majewski I.J., Mittempergher L., Davidson N.M., Bosma A., Willems S.M., Horlings H.M., de Rink I., Greger L., Hooijer G.K., Peters D., Nederlof P.M., Hofland I., de Jong J., Wesseling J., Kluin R.J., Brugman W., Kerkhoven R., Nieboer F., Roepman P., Broeks A., Muley T.R., Jassem J., Niklinski J., van Zandwijk N., Brazma A., Oshlack A., van den Heuvel M. and Bernards R. (2013). Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J. Pathol. 230, 270-276.
107. Makrilia N., Kollias A., Manolopoulos L. and Syrigos K. (2009). Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 27, 1023-1037.
108. Mantovani A., Allavena P., Sica A. and Balkwill F. (2008). Cancerrelated inflammation. Nature 454, 436-444.
109. Marshall A.D., van der Ent M.A. and Grosveld G.C. (2012). PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma. Mol. Carcinog. 51, 807-815.
110. Miyake M., Ishii M., Koyama N., Kawashima K., Kodama T., Anai S., Fujimoto K., Hirao Y. and Sugano K. (2010). 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J. Pharmacol. Exp. Ther. 332, 795-802.
111. Moffa A.B. and Ethier S.P. (2007). Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J. Cell. Physiol. 210, 720-731.
112. Mohanan V., Temburni M.K., Kappes J.C. and Galileo D.S. (2013). L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor. Clin. Exp. Metastasis 30, 507-520.
113. Morrison R.S., Yamaguchi F., Bruner J.M., Tang M., McKeehan W. and Berger M.S. (1994). Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res. 54, 2794-2799.
114. Mouillet J.F., Donker R.B., Mishima T., Cronqvist T., Chu T. and Sadovsky Y. (2013). The unique expression and function of miR-424 in human placental trophoblasts. Biol. Reprod. 89, 25.
115. Myers J.M., Martins G.G., Ostrowski J. and Stachowiak M.K. (2003). Nuclear trafficking of FGFR1: a role for the transmembrane domain. J. Cell. Biochem. 88, 1273-1291.
116. Nakamura K., Yashiro M., Matsuoka T., Tendo M., Shimizu T., Miwa A. and Hirakawa K. (2006). A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131, 1530-1541.
117. Nguyen P.T., Tsunematsu T., Yanagisawa S., Kudo Y., Miyauchi M., Kamata N. and Takata T. (2013). The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br. J. Cancer 109, 2248-2258.
118. Nonomura N., Lu J., Tanaka A., Yamanishi H., Sato B., Sonoda T. and Matsumoto K. (1990). Interaction of androgen-induced autocrine heparin-binding growth factor with fibroblast growth factor receptor on androgen-dependent Shionogi carcinoma 115 cells. Cancer Res. 50, 2316-2321.
119. Obrink B. (1997). CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr. Opin. Cell. Biol. 9, 616-626.
120. Ogawa T., Takayama K., Takakura N., Kitano S. and Ueno H. (2002). Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther. 9, 633-640.
121. Park S., Kim J.H. and Jang J.H. (2007). Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines. Biochem. Biophys. Res. Commun. 357, 1011-1015.
122. Parker B.C., Engels M., Annala M. and Zhang W. (2014). Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J. Pathol. 232, 4-15.
123. Paschos K.A., Canovas D. and Bird N.C. (2009). The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell. Signal. 21, 665-674.
124. Pelaez-Garcia A., Barderas R., Torres S., Hernandez-Varas P., Teixido J., Bonilla F., de Herreros A.G. and Casal J.I. (2013). FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PLoS One 8, e63695.
125. Peng H., Moffett J., Myers J., Fang X., Stachowiak E.K., Maher P., Kratz E., Hines J., Fluharty S.J., Mizukoshi E., Bloom D.C. and Stachowiak M.K. (2001). Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol. Biol. Cell 12, 449-462.
126. Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., Hawley R.G. and Stewart A.K. (2000). Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95, 992-998.
127. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R. and Rusnati M. (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159-178.
128. Preusser M., Berghoff A.S., Berger W., Ilhan-Mutlu A., Dinhof C., Widhalm G., Dieckmann K., Wohrer A., Hackl M., von Deimling A., Streubel B. and Birner P. (2014). High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer 83, 83-89.
129. Prudovsky I.A., Savion N., LaVallee T.M. and Maciag T. (1996). The nuclear trafficking of extracellular fibroblast growth factor (FGF)-1 correlates with the perinuclear association of the FGF receptor-1alpha isoforms but not the FGF receptor-1beta isoforms. J. Biol. Chem. 271, 14198-14205.
130. Qian Z.R., Sano T., Asa S.L., Yamada S., Horiguchi H., Tashiro T., Li C.C., Hirokawa M., Kovacs K. and Ezzat S. (2004). Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J. Clin. Endocrinol. Metab. 89, 1904-1911.
131. Qian X., Anzovino A., Kim S., Suyama K., Yao J., Hulit J., Agiostratidou G., Chandiramani N., McDaid H.M., Nagi C., Cohen H.W., Phillips G.R., Norton L. and Hazan R.B. (2014). N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene 33, 3411-3421.
132. Rachagani S., Macha M.A., Ponnusamy M.P., Haridas D., Kaur S., Jain M. and Batra S.K. (2012). MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis 33, 1953-1964.
133. Radhakrishnan P., Grandgenett P.M., Mohr A.M., Bunt S.K., Yu F., Chowdhury S. and Hollingsworth M.A. (2013). Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int. J. Cancer 133, 2824-2833.
134. Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M. and Malcolm S. (1994). Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat. Genet. 8, 98-103.
135. Reed J.R., Leon R.P., Hall M.K. and Schwertfeger K.L. (2009). Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res. 11, R21.
136. Reed J.R., Stone M.D., Beadnell T.C., Ryu Y., Griffin T.J. and Schwertfeger K.L. (2012). Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner. PLoS One 7, e45877.
137. Reilly J.F. and Maher P.A. (2001). Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J. Cell Biol. 152, 1307-1312.
138. Rosini P., Bonaccorsi L., Baldi E., Chiasserini C., Forti G., De Chiara G., Lucibello M., Mongiat M., Iozzo R.V., Garaci E., Cozzolino F. and Torcia M.G. (2002). Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 53, 310-321.
139. Rousseau B., Larrieu-Lahargue F., Javerzat S., Guilhem-Ducleon F., Beermann F. and Bikfalvi A. (2004). The tyrp1-Tag/tyrp1-FGFR1-DN bigenic mouse: a model for selective inhibition of tumor development, angiogenesis, and invasion into the neural tissue by blockade of fibroblast growth factor receptor activity. Cancer Res. 64, 2490-2495.
140. Salomon D.S. (2000). Cell-cell and cell-extracellular matrix adhesion molecules communicate with growth factor receptors: an interactive signaling Web. Cancer Invest. 18, 591-593.
141. Savagner P., Valles A.M., Jouanneau J., Yamada K.M. and Thiery J.P. (1994). Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol. Biol. Cell 5, 851-862.
142. Schildhaus H.U., Heukamp L.C., Merkelbach-Bruse S., Riesner K., Schmitz K., Binot E., Paggen E., Albus K., Schulte W., Ko Y.D., Schlesinger A., Ansen S., Engel-Riedel W., Brockmann M., Serke M., Gerigk U., Huss S., Goke F., Perner S., Hekmat K., Frank K.F., Reiser M., Schnell R., Bos M., Mattonet C., Sos M., Stoelben E., Wolf J., Zander T. and Buettner R. (2012). Definition of a fluorescence in-situ hybridization score identifies high-and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. 25, 1473-1480.
143. Schultheis A.M., Bos M., Schmitz K., Wilsberg L., Binot E., Wolf J., Buttner R. and Schildhaus H.U. (2014). Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod. Pathol. 27, 214-221.
144. Schwertfeger K.L., Xian W., Kaplan A.M., Burnett S.H., Cohen D.A. and Rosen J.M. (2006). A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Res. 66, 5676-5685.
145. Scuto A., Krejci P., Popplewell L., Wu J., Wang Y., Kujawski M., Kowolik C., Xin H., Chen L., Wang Y., Kretzner L., Yu H., Wilcox W.R., Yen Y., Forman S. and Jove R. (2011). The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25, 538-550.
146. Shan S., Robson N.D., Cao Y., Qiao T., Li C.Y., Kontos C.D., Garcia-Blanco M. and Dewhirst M.W. (2004). Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. FASEB J. 18, 326-328.
147. Simon R., Richter J., Wagner U., Fijan A., Bruderer J., Schmid U., Ackermann D., Maurer R., Alund G., Knonagel H., Rist M., Wilber K., Anabitarte M., Hering F., Hardmeier T., Schonenberger A., Flury R., Jager P., Fehr J.L., Schraml P., Moch H., Mihatsch M.J., Gasser T. and Sauter G. (2001). High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 61, 4514-4519.
148. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., Liu E.M., Reichel J., Porrati P., Pellegatta S., Qiu K., Gao Z., Ceccarelli M., Riccardi R., Brat D.J., Guha A., Aldape K., Golfinos J.G., Zagzag D., Mikkelsen T., Finocchiaro G., Lasorella A., Rabadan R. and Iavarone A. (2012). Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235.
149. Sonvilla G., Allerstorfer S., Heinzle C., Stattner S., Karner J., Klimpfinger M., Wrba F., Fischer H., Gauglhofer C., Spiegl-Kreinecker S., Grasl-Kraupp B., Holzmann K., Grusch M., Berger W. and Marian B. (2010). Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br. J Cancer 102, 1145-1156.
150. Stachowiak M.K., Maher P.A., Joy A., Mordechai E. and Stachowiak E.K. (1996). Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells. Mol. Biol. Cell 7, 1299-1317.
151. Stadler C.R., Knyazev P., Bange J. and Ullrich A. (2006). FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell. Signal. 18, 783-794.
152. Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z., Alitalo K., Taipale J., Keski-Oja J. and Lehti K. (2010). FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc. Natl. Acad. Sci. USA 107, 15786-15791.
153. Suyama K., Shapiro I., Guttman M. and Hazan R.B. (2002). A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2, 301-314.
154. Taeger J., Moser C., Hellerbrand C., Mycielska M.E., Glockzin G., Schlitt H.J., Geissler E.K., Stoeltzing O. and Lang S.A. (2011). Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther. 10, 2157-2167.
155. Takahashi A., Sasaki H., Kim S.J., Kakizoe T., Miyao N., Sugimura T., Terada M. and Tsukamoto T. (1999). Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem. Biophys. Res. Commun. 257, 855-859.
156. Takanami I., Tanaka F., Hashizume T. and Kodaira S. (1997). Tumor angiogenesis in pulmonary adenocarcinomas: relationship with basic fibroblast growth factor, its receptor, and survival. Neoplasma 44, 295-298.
157. Tan C.C., Walsh M.J. and Gelb B.D. (2009). Fgfr3 is a transcriptional target of Ap2delta and Ash2l-containing histone methyltransferase complexes. PLoS One 4, e8535.
158. Taniguchi C.M., Kondo T., Sajan M., Luo J., Bronson R., Asano T., Farese R., Cantley L.C. and Kahn C.R. (2006). Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 3, 343-353.
159. Thomson S., Petti F., Sujka-Kwok I., Mercado P., Bean J., Monaghan M., Seymour S.L., Argast G.M., Epstein D.M. and Haley J.D. (2011). A systems view of epithelial-mesenchymal transition signaling states. Clin. Exp. Metastasis. 28, 137-155.
160. Tomlinson D.C., L'Hote C.G., Kennedy W., Pitt E. and Knowles M.A. (2005). Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factorinduced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 65, 10441-10449.
161. Tomlinson D.C., Lamont F.R., Shnyder S.D. and Knowles M.A. (2009). Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 69, 4613-4620.
162. Tomlinson D.C., Baxter E.W., Loadman P.M., Hull M.A. and Knowles M.A. (2012). FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. PLoS One 7, e38972.
163. Trueb B. (2011). Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell. Mol. Life Sci. 68, 951-964.
164. Turner N. and Grose R. (2010). Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10, 116-129.
165. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., Natrajan R., Marchio C., Iorns E., Mackay A., Gillett C., Grigoriadis A., Tutt A., Reis-Filho J.S. and Ashworth A. (2010). FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094.
166. Valles A.M., Boyer B., Badet J., Tucker G.C., Barritault D. and Thiery J.P. (1990). Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc. Natl. Acad. Sci. USA 87, 1124-1128.
167. van Rhijn B.W., van Tilborg A.A., Lurkin I., Bonaventure J., de Vries A., Thiery J.P., van der Kwast T.H., Zwarthoff E.C. and Radvanyi F. (2002). Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet. 10, 819-824.
168. Veerla S., Lindgren D., Kvist A., Frigyesi A., Staaf J., Persson H., Liedberg F., Chebil G., Gudjonsson S., Borg A., Mansson W., Rovira C. and Hoglund M. (2009). MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124, 2236-2242.
169. Wang Y. and Becker D. (1997). Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 3, 887-893.
170. Wang J., Yu W., Cai Y., Ren C. and Ittmann M.M. (2008). Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10, 847-856.
171. Wang J., Liu X.T., Huang H., Xiao G., Zhou Z.Y., Chen Y., Yu Z.H., He S.L., Chen A.A., Wang D.D., He Y., Zhang Z.C. and Hong A. (2011). Antitumor activity of a recombinant soluble ectodomain of mutant human fibroblast growth factor receptor-2 IIIc. Mol. Cancer Ther. 10, 1656-1666.
172. Wang J., Li J., Wang X., Zheng C. and Ma W. (2013). Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. Biochem. Biophys. Res. Commun. 439, 47-53.
173. Wei W., Liu W., Cassol C.A., Zheng W., Asa S.L. and Ezzat S. (2012). The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-kappaB signaling. Mol. Cell. Biol. 32, 4662-4673.
174. Wen D., Li S., Ji F., Cao H., Jiang W., Zhu J. and Fang X. (2013). miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer. Tumour Biol. 34, 793-803.
175. Wiedemann M. and Trueb B. (2000). Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. Genomics 69, 275-279.
176. Wiedlocha A., Falnes P.O., Rapak A., Munoz R., Klingenberg O. and Olsnes S. (1996). Stimulation of proliferation of a human osteosarcoma cell line by exogenous acidic fibroblast growth factor requires both activation of receptor tyrosine kinase and growth factor internalization. Mol. Cell. Biol. 16, 270-280.
177. Williams S.V., Hurst C.D. and Knowles M.A. (2013). Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795-803.
178. Winter S.F., Acevedo V.D., Gangula R.D., Freeman K.W., Spencer D.M. and Greenberg N.M. (2007). Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 26, 4897-4907.
179. Wu Y.M., Su F., Kalyana-Sundaram S., Khazanov N., Ateeq B., Cao X., Lonigro R.J., Vats P., Wang R., Lin S.F., Cheng A.J., Kunju L.P., Siddiqui J., Tomlins S.A., Wyngaard P., Sadis S., Roychowdhury S., Hussain M.H., Feng F.Y., Zalupski M.M., Talpaz M., Pienta K.J., Rhodes D.R., Robinson D.R. and Chinnaiyan A.M. (2013). Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647.
180. Xian W., Schwertfeger K.L. and Rosen J.M. (2007). Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. Mol. Endocrinol. 21, 987-1000.
181. Xie L., Su X., Zhang L., Yin X., Tang L., Zhang X., Xu Y., Gao Z., Liu K., Zhou M., Gao B., Shen D., Zhang L., Ji J., Gavine P.R., Zhang J., Kilgour E., Zhang X. and Ji Q. (2013). FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19, 2572-2583.
182. Yamada S.M., Yamaguchi F., Brown R., Berger M.S. and Morrison R.S. (1999). Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression. Glia 28, 66-76.
183. Yang F., Zhang Y., Ressler S.J., Ittmann M.M., Ayala G.E., Dang T.D., Wang F. and Rowley D.R. (2013). FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 73, 3716-3724.
184. Yashiro M., Shinto O., Nakamura K., Tendo M., Matsuoka T., Matsuzaki T., Kaizaki R., Miwa A. and Hirakawa K. (2010). Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int. J. Cancer 126, 1004-1016.
185. Yasumoto H., Matsubara A., Mutaguchi K., Usui T. and McKeehan W.L. (2004). Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 61, 236-242.
186. Ye Y.W., Zhou Y., Yuan L., Wang C.M., Du C.Y., Zhou X.Y., Zheng B.Q., Cao X., Sun M.H., Fu H. and Shi Y.Q. (2011). Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. Cancer 117, 5304-5313.
187. Yin R., Bao W., Xing Y., Xi T. and Gou S. (2012). MiR-19b-1 inhibits angiogenesis by blocking cell cycle progression of endothelial cells. Biochem. Biophys. Res. Commun. 417, 771-776.
188. Yin Y., Betsuyaku T., Garbow J.R., Miao J., Govindan R. and Ornitz D.M. (2013). Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. Cancer Res. 73, 5730-5741.
189. Zaid T.M., Yeung T.L., Thompson M.S., Leung C.S., Harding T., Co N.N., Schmandt R.S., Kwan S.Y., Rodriguez-Aguay C., Lopez-Berestein G., Sood A.K., Wong K.K., Birrer M.J. and Mok S.C. (2013). Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin. Cancer Res. 19, 809-820.
190. Zammit C., Barnard R., Gomm J., Coope R., Shousha S., Coombes C. and Johnston C. (2001). Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J. Pathol. 194, 27-34.
191. Zecchini S., Bombardelli L., Decio A., Bianchi M., Mazzarol G., Sanguineti F., Aletti G., Maddaluno L., Berezin V., Bock E., Casadio C., Viale G., Colombo N., Giavazzi R. and Cavallaro U. (2011). The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol. Med. 3, 480-494.
192. Zhang C., Fu L., Fu J., Hu L., Yang H., Rong T.H., Li Y., Liu H., Fu S.B., Zeng Y.X. and Guan X.Y. (2009). Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin. Cancer Res. 15, 4017-4027.
193. Zhang J., Zhang L., Su X., Li M., Xie L., Malchers F., Fan S., Yin X., Xu Y., Liu K., Dong Z., Zhu G., Qian Z., Tang L., Schottle J., Zhan P., Ji Q., Kilgour E., Smith P.D., Brooks A.N., Thomas R.K. and Gavine P.R. (2012). Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 18, 6658-6667.
194. Zhao Q., Caballero O.L., Davis I.D., Jonasch E., Tamboli P., Yung W.K., Weinstein J.N., Strausberg R.L. and Yao J. (2013). Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin. Cancer Res. 19, 2460-2472.
195. Zhong X. and Rescorla F.J. (2012). Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell. Signal. 24, 393-401.
196. Zhu X., Lee K., Asa S.L. and Ezzat S. (2007). Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am. J. Pathol. 170, 1618-1628.
197. Zhu X., Asa S.L. and Ezzat S. (2009). Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol. Endocrinol. 23, 1397-1405.
198. Zhu X., Asa S.L. and Ezzat S. (2010a). Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanomaassociated antigen A in breast cancer. Am. J. Pathol. 176, 2333-2343.
199. Zhu X., Zheng L., Asa S.L. and Ezzat S. (2010b). Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. Am. J. Pathol. 177, 2860-2869.